
    
      【Phase I Phase】 To evaluate safety and pharmacokinetics when PRI-724 is administered to
      patients with HCV or HBV liver cirrhosis , and determine the recommended dose of PRI-724.

      【Phase IIa phase】 To evaluate the efficacy and safety of the recommended dose of PRI-724
      administered to patients with HCV or HBV liver cirrhosis.
    
  